myasthenia gravis mg longterm neuromuscular junction disease leads varying degrees skeletal muscle commonly affected muscles eyes face result double vision drooping eyelids difficulties talking onset affected often large thymus develop myasthenia gravis autoimmune disease neuromuscular junction results antibodies block destroy nicotinic acetylcholine receptors achr junction nerve prevents nerve impulses triggering muscle cases due immunoglobulin antibodies attack achr postsynaptic membrane causing complementmediated damage muscle rarely inherited genetic defect neuromuscular junction results similar condition known congenital babies mothers myasthenia may symptoms first months life known neonatal diagnosis supported blood tests specific antibodies edrophonium test nerve conduction mg generally treated medications known acetylcholinesterase inhibitors neostigmine immunosuppressants prednisone azathioprine may also surgical removal thymus may improve symptoms certain plasmapheresis highdose intravenous immunoglobulin may used sudden flares breathing muscles become significantly weak mechanical ventilation may intubated acetylcholinesterase inhibitors may temporarily held reduce airway mg affects people per newly diagnosed people per million diagnosis become common due increased mg commonly occurs women age men age uncommon treatment affected lead relatively normal lives normal life word greek mys muscle astheneia weakness latin gravis initial main symptom mg painless weakness specific muscles muscle weakness becomes progressively worse periods physical activity improves periods rest typically weakness fatigue worse toward end mg generally starts ocular eye weakness might progress severe generalized form characterized weakness extremities muscles govern basic life twothirds individuals initial symptom mg related muscles around eyelid drooping ptosis may occur due weakness levator palpebrae double vision due weakness extraocular eye symptoms tend get worse watching television reading driving particularly bright consequently affected individuals choose wear term ocular myasthenia gravis describes subtype mg muscle weakness confined eyes ie extraocular muscles levator palpebrae superioris orbicularis typically subtype evolves generalized mg usually weakness muscles involved swallowing may lead swallowing difficulty dysphagia typically means food may left mouth attempt food liquids may regurgitate nose rather go throat velopharyngeal weakness muscles move jaw muscles mastication may cause difficulty chewing individuals mg chewing tends become tiring chewing tough fibrous difficulty swallowing chewing speaking first symptom onesixth weakness muscles involved speaking may lead dysarthria speech may slow nasal cases singing hobby profession must due weakness muscles facial expression muscles mastication facial weakness may manifest inability hold mouth hanging jaw sign snarling expression attempting drooping eyelids facial weakness may make individual appear sleepy difficulty holding head upright may muscles control breathing limb movements also affected rarely present first symptoms mg develop months myasthenic crisis paralysis respiratory muscles occurs necessitating assisted ventilation sustain crises may triggered various biological stressors infection fever adverse reaction medication emotional mg autoimmune synaptopathy disorder occurs immune system malfunctions generates antibodies attack bodys tissues antibodies mg attack normal human protein nicotinic acetylcholine receptor related protein called musk musclespecific less frequent antibodies found agrin titin human leukocyte antigen haplotypes associated increased susceptibility myasthenia gravis autoimmune disorders relatives people myasthenia gravis higher percentage immune thymus gland cells form part bodys immune system myasthenia gravis thymus gland large abnormal sometimes contains clusters immune cells indicate lymphoid hyperplasia thymus gland may give wrong instructions immune neuromuscular junction axon muscle cell membrane synaptic vesicle nicotinic acetylcholine receptor mitochondrion juvenile thymus shrinks age nicotinic acetylcholine receptor women pregnant already mg third cases known experience exacerbation symptoms cases usually occurs first trimester signs symptoms pregnant mothers tend improve second third trimesters complete remission occur immunosuppressive therapy maintained throughout pregnancy reduces chance neonatal muscle weakness controls mothers infants mothers affected condition born transient neonatal myasthenia tnm generally produces feeding respiratory difficulties develop hours several days child tnm typically responds well acetylcholinesterase inhibitors condition generally resolves period three weeks antibodies diminish generally result rarely infant born arthrogryposis multiplex congenita secondary profound intrauterine weakness due maternal antibodies target infants acetylcholine receptors cases mother remains mg difficult diagnose symptoms subtle hard distinguish normal variants neurological three types myasthenic symptoms children congenital myasthenias cause muscle weakness fatigability similar signs congenital myasthenia usually present first years childhood although may recognized diagnosed mg person assessed neurological status level illness established usually done using accepted myasthenia gravis foundation america clinical classification scalecitation needed physical examination check mg doctor might ask person perform repetitive movements instance doctor may ask one look fixed point seconds relax muscles forehead person mg ptosis eyes might involuntarily using forehead muscles compensate weakness clinical examiner might also try elicit curtain sign person holding one persons eyes open case mg lead eye diagnosis suspected serology performed muscle fibers people mg easily fatigued repetitive nerve stimulation test help diagnose singlefiber electromyography considered sensitive although specific test thin needle electrode inserted different areas particular muscle record action potentials several samplings different individual muscle fibers two muscle fibers belonging motor unit identified temporal variability firing patterns measured frequency proportion particular abnormal action potential patterns called jitter blocking diagnostic jitter refers abnormal variation time interval action potentials adjacent muscle fibers motor unit blocking refers failure nerve impulses elicit action potentials adjacent muscle fibers motor applying ice minutes muscles reportedly sensitivity specificity respectively identification mg acetylcholinesterase thought inhibited lower temperature basis diagnostic test generally performed eyelids ptosis present deemed positive rise eyelid occurs ice test requires intravenous administration edrophonium chloride neostigmine drugs block breakdown acetylcholine cholinesterase acetylcholinesterase test longer typically performed use lead lifethreatening bradycardia slow heart rate requires immediate emergency production edrophonium discontinued chest xray may identify widening mediastinum suggestive thymoma computed tomography magnetic resonance imaging mri sensitive ways identify thymomas generally done mri cranium orbits may also performed exclude compressive inflammatory lesions cranial nerves ocular forced vital capacity may monitored intervals detect increasing muscular weakness acutely negative inspiratory force may used determine adequacy ventilation performed individuals muscle weakness worsens activity abnormal muscle fatigue myasthenia symptom shared neuromuscular diseases metabolic myopathies mcardle disease gsdv abnormal muscle fatigue rather fixed muscle also like myasthenia exercise intolerance mcardle disease improves regular physical activity performed safely using activity adaptations getting second wind rule six second small minority patients mcardle disease also comorbidity ptosis drooping upper diseases involve abnormal muscle fatigue may described exerciseinduced muscle weakness reversible muscle weakness muscle weakness improves rest include endocrine myopathies hoffman syndrome tubular aggregate myopathy tam ischemia intermittent claudication popliteal artery entrapment syndrome chronic venous insufficiency poor diet malabsorption diseases lead vitamin deficiency osteomalic myopathy although limbgirdle muscular dystrophies lgmds involve fixed muscle weakness also involves muscle limbgirdle muscular dystrophydystroglycanopathies formerly known myofibrillar myopathy dimethylglycine dehydrogenase erythrocyte lactate transporter myopathy myalgia increased serum creatine kinase without episodic rhabdomyolysis also include muscle fatigue xlinked episodic muscle weakness emwx includes general muscle weakness ptosis fluctuations strength individuals fatiguability demonstrable phenotype features comparable congenital myasthenic syndromes signs symptoms myasthenia presenting infancy childhood may one congenital myasthenic syndromes inherited either autosomal dominant recessive manner currently two dozen types congenital myasthenic treatment medication andor surgery medication consists mainly acetylcholinesterase inhibitors directly improve muscle function immunosuppressant drugs reduce autoimmune thymectomy surgical method treat worsening may occur medication fluoroquinolones aminoglycosides people generalized mg considered autologous hematopoietic stem cell transplantation hsct sometimes used severe treatmentrefractory mg available data provide preliminary evidence hsct effective therapeutic option carefully selected efgartigimod alfa vyvgart approved medical use united states december efgartigimod alfahyaluronidase vyvgart hytrulo approved medical use united states june rozanolixizumab rystiggo approved medical use united states june acetylcholinesterase inhibitors provide symptomatic benefit may fully remove persons weakness might fully remove symptoms mg still may allow person ability perform normal daily usually acetylcholinesterase inhibitors started low dose increased desired result achieved taken minutes meal symptoms mild eating helpful difficulty swallowing due illness another medication used mg atropine reduce muscarinic side effects acetylcholinesterase pyridostigmine relatively longacting drug compared cholinergic agonists halflife around four hours relatively side generally discontinued mechanically ventilated known increase amount salivary highquality studies directly compared cholinesterase inhibitors treatments placebo practical benefit may significant conducting studies would withheld people would steroid prednisone might also used achieve better result lead worsening symptoms takes weeks achieve maximal research suggests patients positively respond immune due myriad symptoms steroid treatments cause preferred method immune suppressing medications may also used including myasthenia serious myasthenic crisis plasmapheresis used remove putative antibodies circulation also intravenous immunoglobulins ivigs used bind circulating antibodies treatments relatively shortlived benefits typically measured weeks often associated high costs make prohibitive generally reserved mg requires thymomas seen people mg often given chest xray ct scan evaluate need surgical removal thymus glands cancerous tissue may even surgery performed remove thymoma generally lead remission surgery case mg involves removal thymus although clear benefit indicated except presence randomized controlled trial however found people mg educated regarding fluctuating nature symptoms including weakness exerciseinduced fatigue exercise participation encouraged frequent people generalized mg evidence indicates partial home program including training diaphragmatic breathing pursedlip breathing intervalbased muscle therapy may improve respiratory muscle strength chest wall mobility respiratory pattern respiratory people myasthenia gravis older forms iodinated contrast used medical imaging caused increased risk exacerbation disease modern forms immediate increased prognosis people mg generally good quality life given good monitoring person mg important least people diagnosed experience myasthenic crisis within two years diagnosis requiring rapid medical generally disabling period mg might years initial early detected cases died lung problems number estimated around improvement attributed increased awareness medications manage mg occurs ethnic groups sexes commonly affects women people years old either sex known occur age younger people rarely thymoma prevalence united states estimated cases per estimated americans united kingdom estimated cases mg occur per first write mg thomas willis samuel wilks erb term myasthenia gravis pseudoparalytica proposed jolly german mary walker treated person mg physostigmine simpson nastuck detailed autoimmune nature patrick lindstrom used rabbits show immunization purified musclelike acetylcholine receptors caused development mglike immunomodulating substances drugs prevent acetylcholine receptor modulation immune system currently research recently inhibitors treatment research safe used treatment ephedrine seems benefit people medications properly studied laboratory mg mostly studied model organisms rodents addition scientists developed vitro functional allhuman neuromuscular junction assay human embryonic stem cells somaticmuscle stem cells addition pathogenic antibodies acetylcholine receptor activation complement system neuromuscular coculture shows symptoms weaker muscle httpsenwikipediaorgwikimyastheniagravis